Conference abstract · 25 Sep 2014
Conference abstract
Developing biosimilars: Considerations, opportunities and challenges
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biologic drugs have emerged as a major therapeutic class in the market. Currently, there are 4 biologics among the top ten best-selling drugs. It is estimated that by 2016, 7 of the top-ten-selling drugs will be biologics. With a significant number of biologic drugs losing patent protection in the coming years and the publication of the FDA guidance on the development of biosimilars, the drug industry is increasingly focusing on biosimilars as a major investment opportunity. In particular, the monoclonal antibody family of therapeutics has attracted a lot of attention partly due to their more mature manufacturing processes and near-term patent expirations on several blockbusters in this class. While the recent FDA guidance is helpful in defining a development path for biosimilar development, key considerations must be made in the context of the guidance and translated into executable development plans and milestones for a given biosimilar product of interest. Strategically important factors include manufacturing processes, analytical capabilities, and technical and regulatory know-how. Although the primary goal is to demonstrate there are no clinical meaningful differences between the proposed biological product and the reference product in terms of safety, purity and potency, gaining interchangeability and potential exclusivity is critical in ensuring commercial success. There are many challenges in developing biosimilars, the importance of technical know-how and practical execution will be discussed
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Jun 2023
From biosimilars to affordable copies of biologics; access opportunities, scientific and regulatory challenges and emerging solutions
Conference abstract · 7 Nov 2016
Challenges and opportunities for biosimilar industry in China
Conference abstract · 17 Dec 2014
Biosimilars: Opportunities and challenges
Conference abstract · 21 Oct 2013
Biosimilars and non-innovator biotherapeutics in MENA region: Opportunities and challenges
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ming Wang”
